SCYNEXIS Stock

SCYNEXIS Operating Expenses

The Total Operating Expenses of SCYNEXIS (SCYX) as of Aug 5, 2026 is 40.86 M USD. In the previous year, Total Operating Expenses was 51.85 M USD — a change of -21.19% (lower).

Operating Expenses

40.86 MUSD

YoY

-21.19%

Last updated:

Total Operating Expenses of SCYNEXIS is 2026 40.86 M USD. Total Operating Expenses of SCYNEXIS was 2025 51.85 M USD. It decreases by -21.19% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Total Operating Expenses of SCYNEXIS is 40.86 M USD in 2026.

Total Operating Expenses of SCYNEXIS changed from 51.85 M USD to 40.86 M USD, representing a -21.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Income Statement — SCYNEXIS

All Key Metrics — SCYNEXIS